April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Vascular changes in the macula of eyes with diabetic macular edema treated with varying doses of ranibizumab
Author Affiliations & Notes
  • Liz Julieth Zapata
    Ocular Imaging Research and Reading Center, Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE
  • Yasir Sepah
    Ocular Imaging Research and Reading Center, Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE
  • Jose Maya
    Ocular Imaging Research and Reading Center, Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE
  • Mostafa Saad Hanout
    Ocular Imaging Research and Reading Center, Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE
  • Mohammad Ali Sadiq
    Ocular Imaging Research and Reading Center, Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE
  • Salman Sarwar
    Ocular Imaging Research and Reading Center, Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE
  • Nithya Rajagopalan
    Ocular Imaging Research and Reading Center, Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE
  • Kathleen Ellen Guinn
    Ocular Imaging Research and Reading Center, Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE
  • Quan Dong Nguyen
    Ocular Imaging Research and Reading Center, Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE
  • Diana V Do
    Ocular Imaging Research and Reading Center, Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE
  • Footnotes
    Commercial Relationships Liz Zapata, None; Yasir Sepah, None; Jose Maya, None; Mostafa Hanout, None; Mohammad Sadiq, None; Salman Sarwar, None; Nithya Rajagopalan, None; Kathleen Guinn, None; Quan Dong Nguyen, Genentech (F), Regeneron (F); Diana Do, Genentech (F), Regeneron (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1748. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Liz Julieth Zapata, Yasir Sepah, Jose Maya, Mostafa Saad Hanout, Mohammad Ali Sadiq, Salman Sarwar, Nithya Rajagopalan, Kathleen Ellen Guinn, Quan Dong Nguyen, Diana V Do, READ-3 Study Group; Vascular changes in the macula of eyes with diabetic macular edema treated with varying doses of ranibizumab. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1748.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

The aim of this study is to assess the changes in vessel diameter in the macula of patients with diabetic macular edema (DME) treated with 2 different doses of ranibizumab (RBZ).

 
Methods
 

Fundus photos from 38 patients (38 eyes) enrolled in the READ-3 study (comparison of 0.5mg vs. 2.0mg of RBZ for DME) were analyzed. Photos were divided in two groups according to treatment arms (Group A=0.5mg; Group B=2.0mg). All eyes received 6 monthly injections starting at the baseline visit. Macular retinal arterial equivalent (MRAE) and macular retinal venular equivalent (MRVE) were measured using Interactive Vessel Analysis (IVAN) software centered on the fovea; the 2 largest venules and arterioles one-half to one disc diameter from the fovea were measured. Parametric tests (paired t-test, independent t-test) were performed to compare the MRVE and MRAE between the two groups.

 
Results
 

17 patients were included in group A; 21 in group B. The mean age was 62 and 64 in group A and B, respectively. 10 patients were male in group A; 13 males in group B. There was reduction in both MRAE and MRVE at month 6 compared to baseline for both doses of RBZ (table). The changes were statistically significant in MRVE and demonstrated a trend towards significance in MRAE. However, the changes (MRAE and MRVE) that occurred in group A were similar to those in group B and did not demonstrate any statistically significant differences (p=0.210 for MRAE and p=0.614 for MRVE).

 
Conclusions
 

Treatment of DME with RBZ appears to induce similar reduction in MRVE and MRAE, regardless of dose. Such findings with fovea-centered vascular grading imply that low and high dose of RBZ may have similar effects on macular vasculature in eyes with DME.

  
Keywords: 499 diabetic retinopathy • 505 edema • 585 macula/fovea  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×